Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms
Name:
Frye_JNeuroimmun_2019.pdf
Size:
4.367Mb
Format:
PDF
Description:
Final Published Version
Author
Shimasaki, CraigFrye, Richard E
Trifiletti, Rosario
Cooperstock, Michael
Kaplan, Gary
Melamed, Isaac
Greenberg, Rosalie
Katz, Amiram
Fier, Eric
Kem, David
Traver, David
Dempsey, Tania
Latimer, M Elizabeth
Cross, Amy
Dunn, Joshua P
Bentley, Rebecca
Alvarez, Kathy
Reim, Sean
Appleman, James
Affiliation
Univ Arizona, Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Child Hlth,Coll Med PhoenixIssue Date
2020-02-15Keywords
Antineuronal antibodiesAutoimmune encephalopathy
Basal ganglia encephalitis
Basal ganglia encephalopathy
CaMKII
Cunningham Panel
PANDAS, PANS
Metadata
Show full item recordPublisher
ELSEVIERCitation
Shimasaki, C., Frye, R. E., Trifiletti, R., Cooperstock, M., Kaplan, G., Melamed, I., ... & Traver, D. (2020). Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms. Journal of Neuroimmunology, 339, 577138.Journal
JOURNAL OF NEUROIMMUNOLOGYRights
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Comparison of pre- and post-treatment status revealed that the Cunningham Panel results correlated with changes in patient's neuropsychiatric symptoms. Based upon the change in the number of positive tests, the overall accuracy was 86%, the sensitivity and specificity were 88% and 83% respectively, and the Area Under the Curve (AUC) was 93.4%. When evaluated by changes in autoantibody levels, we observed an overall accuracy of 90%, a sensitivity of 88%, a specificity of 92% and an AUC of 95.7%. Assay reproducibility for the calcium/calmodulin-dependent protein kinase II (CaMKII) revealed a correlation coefficient of 0.90 (p < 1.67 × 10-6) and the ELISA assays demonstrated test-retest reproducibility comparable with other ELISA assays.Note
Open access articleISSN
0165-5728EISSN
1872-8421PubMed ID
31884258Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1016/j.jneuroim.2019.577138
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).